Melissa K Accordino1, Jason D Wright2, Sowmya Vasan2, Alfred I Neugut2, Grace C Hillyer2, Jim C Hu2, Dawn L Hershman2. 1. Melissa K. Accordino, Jason D. Wright, Alfred I. Neugut, Grace C. Hillyer, and Dawn L. Hershman, Columbia University College of Physicians and Surgeons; Sowmya Vasan, Alfred I. Neugut, Grace C. Hillyer, and Dawn L. Hershman, Columbia University; and Jim C. Hu, Weill Cornell Medicine, New York, NY. mkg2134@cumc.columbia.edu. 2. Melissa K. Accordino, Jason D. Wright, Alfred I. Neugut, Grace C. Hillyer, and Dawn L. Hershman, Columbia University College of Physicians and Surgeons; Sowmya Vasan, Alfred I. Neugut, Grace C. Hillyer, and Dawn L. Hershman, Columbia University; and Jim C. Hu, Weill Cornell Medicine, New York, NY.
Abstract
PURPOSE: The optimal frequency of monitoring patients with metastatic breast cancer (MBC) is unknown; however, data suggest that intensive monitoring does not improve outcomes. We performed a population-based analysis to evaluate patterns and predictors of extreme use of disease-monitoring tests (serum tumor markers [STMs] and radiographic imaging) among women with MBC. METHODS: The SEER-Medicare database was used to identify women with MBC diagnosed from 2002 to 2011 who underwent disease monitoring. Billing dates of STMs (carcinoembryonic antigen and/or cancer antigen 15-3/cancer antigen 27.29) and imaging tests (computed tomography and/or positron emission tomography) were recorded; if more than one STM or imaging test were completed on the same day, they were counted once. We defined extreme use as > 12 STM and/or more than four radiographic imaging tests in a 12-month period. Multivariable analysis was used to identify factors associated with extreme use. In extreme users, total health care costs and end-of-life health care utilization were compared with the rest of the study population. RESULTS: We identified 2,460 eligible patients. Of these, 924 (37.6%) were extreme users of disease-monitoring tests. Factors significantly associated with extreme use were hormone receptor-negative MBC (odds ratio [OR], 1.63; 95% CI, 1.27 to 2.08), history of a positron emission tomography scan (OR, 2.92; 95% CI, 2.40 to 3.55), and more frequent oncology office visits (OR, 3.14; 95% CI, 2.49 to 3.96). Medical costs per year were 59.2% higher in extreme users. Extreme users were more likely to use emergency department and hospice services at the end of life. CONCLUSION: Despite an unknown clinical benefit, approximately one third of elderly women with MBC were extreme users of disease-monitoring tests. Higher use of disease-monitoring tests was associated with higher total health care costs. Efforts to understand the optimal frequency of monitoring are needed to inform clinical practice.
PURPOSE: The optimal frequency of monitoring patients with metastatic breast cancer (MBC) is unknown; however, data suggest that intensive monitoring does not improve outcomes. We performed a population-based analysis to evaluate patterns and predictors of extreme use of disease-monitoring tests (serum tumor markers [STMs] and radiographic imaging) among women with MBC. METHODS: The SEER-Medicare database was used to identify women with MBC diagnosed from 2002 to 2011 who underwent disease monitoring. Billing dates of STMs (carcinoembryonic antigen and/or cancer antigen 15-3/cancer antigen 27.29) and imaging tests (computed tomography and/or positron emission tomography) were recorded; if more than one STM or imaging test were completed on the same day, they were counted once. We defined extreme use as > 12 STM and/or more than four radiographic imaging tests in a 12-month period. Multivariable analysis was used to identify factors associated with extreme use. In extreme users, total health care costs and end-of-life health care utilization were compared with the rest of the study population. RESULTS: We identified 2,460 eligible patients. Of these, 924 (37.6%) were extreme users of disease-monitoring tests. Factors significantly associated with extreme use were hormone receptor-negative MBC (odds ratio [OR], 1.63; 95% CI, 1.27 to 2.08), history of a positron emission tomography scan (OR, 2.92; 95% CI, 2.40 to 3.55), and more frequent oncology office visits (OR, 3.14; 95% CI, 2.49 to 3.96). Medical costs per year were 59.2% higher in extreme users. Extreme users were more likely to use emergency department and hospice services at the end of life. CONCLUSION: Despite an unknown clinical benefit, approximately one third of elderly women with MBC were extreme users of disease-monitoring tests. Higher use of disease-monitoring tests was associated with higher total health care costs. Efforts to understand the optimal frequency of monitoring are needed to inform clinical practice.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Scott D Ramsey; N Lynn Henry; Julie R Gralow; Dana K Mirick; William Barlow; Ruth Etzioni; David Mummy; Rahber Thariani; David L Veenstra Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Patricia A Parker; Andrzej Kudelka; Karen Basen-Engquist; John Kavanagh; Janet de Moor; Lorenzo Cohen Journal: Gynecol Oncol Date: 2005-10-20 Impact factor: 5.482
Authors: Gordon J S Rustin; Maria E L van der Burg; Clare L Griffin; David Guthrie; Alan Lamont; Gordon C Jayson; Gunnar Kristensen; César Mediola; Corneel Coens; Wendi Qian; Mahesh K B Parmar; Ann Marie Swart Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Jeremy W Couper; Anthony W Love; Gillian M Duchesne; Sidney Bloch; Michelle Macvean; Judy V Dunai; Marita Scealy; Anthony Costello; David W Kissane Journal: Med J Aust Date: 2010-09-06 Impact factor: 7.738
Authors: Jeffrey B Smerage; William E Barlow; Gabriel N Hortobagyi; Eric P Winer; Brian Leyland-Jones; Gordan Srkalovic; Sheela Tejwani; Anne F Schott; Mark A O'Rourke; Danika L Lew; Gerald V Doyle; Julie R Gralow; Robert B Livingston; Daniel F Hayes Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 50.717
Authors: Benjamin Margolis; Ling Chen; Melissa K Accordino; Grace Clarke Hillyer; June Y Hou; Ana I Tergas; William M Burke; Alfred I Neugut; Cande V Ananth; Dawn L Hershman; Jason D Wright Journal: Am J Obstet Gynecol Date: 2017-07-11 Impact factor: 8.661
Authors: Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Tal Gross; Grace C Hillyer; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2017-07-27 Impact factor: 4.872
Authors: Stephen B Williams; Yong Shan; Mohamed D Ray-Zack; Hogan K Hudgins; Usama Jazzar; Douglas S Tyler; Stephen J Freedland; Todd A Swanson; Jacques G Baillargeon; Jim C Hu; Sapna Kaul; Ashish M Kamat; John L Gore; Hemalkumar B Mehta Journal: JAMA Surg Date: 2019-08-21 Impact factor: 14.766
Authors: Stephen B Williams; Lauren E Howard; Meagan L Foster; Zachary Klaassen; Jan Sieluk; Amanda M De Hoedt; Stephen J Freedland Journal: JAMA Netw Open Date: 2021-03-01